SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following impressive vehicle delivery numbers for December and Q4, surpassing expectations and fueling community excitement about its substantial year-over-year growth and nearing a million cumulative deliveries. The stock's undervaluation is a key talking point, with many anticipating future profitability bolstered by extended EV subsidies and the unique battery swap infrastructure, despite ongoing debates about market manipulation.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending with mixed community sentiment as the new year unfolds, fueled by widespread speculation regarding its immediate price action. Enthusiasts are vocal about their hopes for a significant rally, anticipating fresh buying interest as year-end tax adjustments conclude. The ongoing conversation reflects both strong community loyalty and debates surrounding its long-term trajectory as a prominent meme coin.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending due to significant community discussion surrounding recent share dilution for executive compensation, leading to frustration over persistent underperformance despite its substantial Bitcoin holdings. Investors are actively debating the company's valuation, with some seeing deep undervaluation due to unpriced energy infrastructure and an AI/HPC pivot, while others express concerns about management and potential further downside amidst heavy short interest.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending with massive volume and significant price action following news of a strategic manufacturing partnership to scale production of its fingerprinting drug screening reader. While many in the community are bullish on its low float, anticipating a short squeeze and further gains, strong concerns are rapidly emerging regarding a recently announced private placement at a lower price, sparking fears of significant dilution.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending with a notable price surge, leading to a highly divided community conversation. Many are expressing frustration, calling it a "scam" due to perceived manipulation and past volatility, while others remain optimistic, citing its real-world utility through Flexa partnerships and potential for future institutional adoption, especially with upcoming regulatory clarity.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending amid significant community discussion around strategic moves to enhance its utility and institutional presence, particularly with the launch of Europe's first ETP. The community also eagerly anticipates a substantial token burn as it approaches a key holder milestone, fueling mixed sentiment and speculation about a potential rally within the Solana ecosystem.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG CRYPTO is trending due to its "Infinite Money Glitch" protocol, which consistently distributes passive Solana rewards to holders, cultivating a highly dedicated and resilient community. Despite recent chart movements, a strong bullish sentiment persists, fueled by anticipation for upcoming LP rewards, the imminent launch of real-time audit technology, and its ambitious aim to integrate with major gaming economies.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is actively trending due to its Q3 earnings, significant advancements in AI and humanoid robotics, and strong pre-order demand for its new X9 EREV hybrid. Community sentiment is divided, with many citing undervaluation and global expansion as key bullish drivers, while others point to frustrating price drops and perceived market manipulation in the Chinese EV sector. Attention remains on upcoming delivery figures and the company's path to sustained profitability amidst new EV incentives.

Pump.fun

PUMP.FUN is actively trending amid ongoing legal challenges, including a major lawsuit with whistleblower revelations and a former developer's sentencing, fueling speculation across the community. Many are debating whether current price action represents a "bear trap" or indicates deeper issues, even as affiliated meme projects within the Solana ecosystem rally for continued growth.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is seeing significant discussion following an unexpected Q3 loss and a cautious Q4 delivery outlook, which has fueled mixed sentiment within the investor community. Despite these challenges, the launch of the company's new AI-powered smart glasses is generating buzz, while renewed government subsidies for electric vehicles are providing a sector-wide tailwind, influencing views on Li Auto's new i6 SUV and broader market position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

Crescent Biopharma (NASDAQ:CBIO) Share Price Crosses Above 200 Day Moving Average - Here's Why...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Brokerages

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have been given a consensus recommendation of "Buy" by the seven brokerages that are currently covering the company, MarketBeat.com...

Braidwell LP Invests $4.22 Million in Crescent Biopharma, Inc. $CBIO

Braidwell LP acquired a new stake in Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange...

BVF Inc. IL Makes New Investment in Crescent Biopharma, Inc. $CBIO

BVF Inc. IL purchased a new stake in Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and...

Fairmount Funds Management Llc Purchases 1,360,000 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) Director Fairmount Funds Management Llc bought 1,360,000 shares of the stock in a transaction on Thursday, December 4th. The shares were...

Crescent Biopharma (NASDAQ:CBIO) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Crescent Biopharma is partnering with the Chinese firm Kelun-Biotech to expand its oncology drug pipeline and accelerate its combination strategy.&nbsp;</li><li>The company also announced a $185 million private placement, expected to close around December 8.</li><li>Stocktwits retail sentiment for the stock was ‘extremely bullish’.</li></ul><a href="https://stocktwits.com/symbol/CBIO">Crescent Biopharma (CBIO)</a> announced a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co. to expand its pipeline of oncology drugs and speed up its combination strategy. The company also announced a $185 million private placement, expected to close around December 8.Shares of Crescent were up over 40% in pre-market trading.The company said it has three distinct programs that are expected to enter the clinic in 2026. In addition, the private financing will boost its cash runway.“We’re excited to share the tremendous progress we’ve made executing on our strategy of building a robust portfolio of next-generation oncology therapeutics," said Joshua Brumm, chief executive officer of Crescent.<h2 class="st-heading-2">Partnership Details</h2>The deal will allow Crescent exclusive rights to research, develop, and commercialize SKB105 (also known as CR-003) in the United States, Europe, and all markets excluding Greater China. This is an integrin beta-6 (ITGB6)-directed antibody-drug conjugate (ADC) with a topoisomerase payload.Meanwhile, Kelun-Biotech will obtain exclusive rights to research, develop, and commercialize CR-001 in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The drug is Crescent’s bispecific antibody that the company says has the potential to be foundational in immuno-oncology.Both Crescent and Kelun-Biotech will retain the right to independently develop CR-001 in combination with proprietary ADC pipeline assets.“CR-001, our PD-1 x VEGF bispecific antibody, has the potential to be a foundational immuno-oncology backbone and the partnership we announced with Kelun-Biotech today has enhanced our pipeline of ADCs and accelerated our efforts to deliver potentially best-in-class novel combination therapies,” said Brumm.<h2 class="st-heading-2">Retail Reaction</h2>Stocktwits retail sentiment for the stock changed from ‘neutral’ to ‘extremely bullish’ while message volume jumped to ‘extremely high’.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_5_01_28_PM_png_71929a932d.webp" alt="Stocktwits retail sentiment for the stock is ‘extremely bullish’ while message volume remained ‘extremely high’."> One user noted they were ‘bullish’ on the stock, adding “In with a starter!”<stembedurl>https://stocktwits.com/KuruHabesha/message/638133096</stembedurl>Another said that the stock was long forgotten in their portfolio.<stembedurl>https://stocktwits.com/walkingprinter/message/638132752</stembedurl>Shares of Crescent Biopharma were down about 47% year-to-date but have gained almost 8% in the last month.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/why-tigr-stock-rose-premarket-trade-today/cLILDuARESm">Here’s Why TIGR Stock Rose In Premarket Today – And Retail Traders Think The Rally’s Just Starting</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today

Crescent Biopharma announced a strategic partnership with the Chinese firm Sichuan Kelun-Biotech Biopharmaceutical Co. to fast-track its global oncology pipeline. 

Equity

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) has been given a consensus recommendation of "Buy" by the seven ratings firms that are currently covering the firm, Marketbeat.com reports...

Crescent Biopharma (NASDAQ:CBIO) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded Crescent Biopharma from a "sell" rating to a "hold" rating in a report on Sunday...

Crescent Biopharma (NASDAQ:CBIO) Announces Earnings Results

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the...

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Current Price	$11.86
Prev Close	$11.60
Open	$11.75
Dividend Yield	0.00%
50-Day Moving Average	$13.04
Beta	0.75
Avg. Volume	63,373.84
PE Ratio	-0.54

52-Week High	$37.00
52-Week Low	$9.81
Market Capitalization	$161.15M
EPS (Annual)	-$58.75
Price to Book	1.46
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CBIO
Crescent Biopharma Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CBIO News

CBIOCrescent Biopharma Inc.